NICOYA年衍药业
/
← All feature readings
Feature article4 min read

Calcifediol and immune homeostasis: from substrate to evidence

Calcifediol links upstream supply with further activation. Its relationship with immunity requires a distinction between metabolic roles, associations and clinical trials—not the idea of turning immunity up.

Locate calcifediol first

Calcifediol is 25(OH)D₃ and can supply a substrate for further activation. Tissue activation and receptor signaling are another mechanistic layer; effects of the active form should not all be attributed directly to calcifediol.

Mechanistic clues are not clinical benefits

Immune research may measure enzymes, receptor signaling, inflammatory markers or clinical outcomes. These endpoints answer different questions. A laboratory change does not establish fewer infections or faster recovery.

Read the actual trial question

Calcifediol formulations have been studied in immune-related settings, including the REsCue randomized trial of extended-release calcifediol during a specific infection. Population, formulation, prespecified endpoints and statistical uncertainty limit generalization. This is not evidence for universal immune boosting.

Ask evidence-based questions

Whether testing is appropriate and how total 25(OH)D relates to the person's health are more useful questions than whether higher is always better. Recurrent symptoms have multiple possible causes and cannot select a calcifediol medicine.